GB9810423D0 - Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy - Google Patents

Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Info

Publication number
GB9810423D0
GB9810423D0 GBGB9810423.5A GB9810423A GB9810423D0 GB 9810423 D0 GB9810423 D0 GB 9810423D0 GB 9810423 A GB9810423 A GB 9810423A GB 9810423 D0 GB9810423 D0 GB 9810423D0
Authority
GB
United Kingdom
Prior art keywords
diathermy
ionizing radiation
therapy
antitumour
gene therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9810423.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Priority to GBGB9810423.5A priority Critical patent/GB9810423D0/en
Publication of GB9810423D0 publication Critical patent/GB9810423D0/en
Priority to NZ508671A priority patent/NZ508671A/en
Priority to EP99922263A priority patent/EP1078091A2/en
Priority to PCT/GB1999/001362 priority patent/WO1999060142A2/en
Priority to CA002374248A priority patent/CA2374248A1/en
Priority to AU39375/99A priority patent/AU763714B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9810423.5A 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy Ceased GB9810423D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9810423.5A GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
NZ508671A NZ508671A (en) 1998-05-15 1999-05-17 Gene therapy vectors for sensitising cancer cells and their use in antitumour therapy
EP99922263A EP1078091A2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
PCT/GB1999/001362 WO1999060142A2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
CA002374248A CA2374248A1 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy
AU39375/99A AU763714B2 (en) 1998-05-15 1999-05-17 Gene therapy vectors and their use in antitumour therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810423.5A GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Publications (1)

Publication Number Publication Date
GB9810423D0 true GB9810423D0 (en) 1998-07-15

Family

ID=10832095

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9810423.5A Ceased GB9810423D0 (en) 1998-05-15 1998-05-15 Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy

Country Status (6)

Country Link
EP (1) EP1078091A2 (en)
AU (1) AU763714B2 (en)
CA (1) CA2374248A1 (en)
GB (1) GB9810423D0 (en)
NZ (1) NZ508671A (en)
WO (1) WO1999060142A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19947668A1 (en) 1999-10-04 2001-04-19 Univ Eberhard Karls Tumor-specific vector for gene therapy
EP1118668A1 (en) * 2000-01-07 2001-07-25 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
EP1244796A2 (en) * 2000-01-07 2002-10-02 ARTEMIS Pharmaceuticals GmbH Transduction of recombinases for inducible gene targeting
US6436695B1 (en) 2001-03-01 2002-08-20 Ultra Biotech Limited Yeast compositions for converting bio-available phosphorus in a culture medium to intracellular phosphorus
US6440713B1 (en) 2001-03-01 2002-08-27 Ultra Biotech Limited Methods and compositions for suppressing growth of pathogenic microbes
US6391618B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Methods and compositions for degrading environmental toxins
US6391617B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Yeast compositions for converting bio-available nitrogen in a culture medium to intracellular nitrogen
US6391619B1 (en) 2001-03-01 2002-05-21 Ultra Biotech Limited Methods and compositions for suppressing growth of algae
CA2483449A1 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
AU2003234319A1 (en) * 2002-05-03 2003-11-17 Board Of Regents, The University Of Texas System Mta1s, a steroid hormone receptor corepressor
US6753008B2 (en) 2002-06-28 2004-06-22 Ultra Biotech Limited Dietary supplements beneficial for the liver
US6649383B1 (en) 2002-06-28 2003-11-18 Ultra Biotech Limited Dietary supplements beneficial for the gastrointestinal system
US6660508B1 (en) 2002-06-28 2003-12-09 Ultra Biotech Limited Dietary supplements for treating hyperlipemia
US6759055B2 (en) 2002-06-28 2004-07-06 Ultra Biotech Limited Dietary supplements for improving kidney function
US6793933B2 (en) 2002-06-28 2004-09-21 Ultra Biotech Limited Dietary supplements for enhancing the immune system
US6709849B2 (en) 2002-06-28 2004-03-23 Ultra Biotech Limited Dietary supplements for regulating male hormone
US6756050B2 (en) 2002-06-28 2004-06-29 Ultra Biotech Limited Dietary supplements for improving memory
US9816077B2 (en) * 2011-08-03 2017-11-14 Ramot At Tel-Aviv University Ltd. Use of integrase for targeted gene expression
US20140350087A9 (en) * 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
AU2014225365B2 (en) * 2013-03-07 2019-09-12 Baylor College Of Medicine Targeting CD138 in cancer
EP3658165A4 (en) 2017-07-26 2021-09-01 Oncorus, Inc. Oncolytic viral vectors and uses thereof
CA3157063A1 (en) * 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
US20230138409A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
US20230134550A1 (en) 2020-03-24 2023-05-04 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015694A1 (en) * 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
DE19530412A1 (en) * 1995-08-18 1997-02-20 Harald Von Prof Dr Melchner Self-deleting retroviral vectors for gene therapy
JP2000500341A (en) * 1995-11-13 2000-01-18 ユニバーシティ・オブ・ロチェスター Generation of mammalian somatic mosaicism by recombinant substrates
US6274354B1 (en) * 1996-09-06 2001-08-14 The Trustees Of The University Of Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses

Also Published As

Publication number Publication date
AU763714B2 (en) 2003-07-31
WO1999060142A2 (en) 1999-11-25
CA2374248A1 (en) 1999-11-25
EP1078091A2 (en) 2001-02-28
AU3937599A (en) 1999-12-06
NZ508671A (en) 2003-05-30
WO1999060142A3 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
GB9810423D0 (en) Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
IL115584A0 (en) Viral vectors and their use in gene therapy
ZA979096B (en) Viral and cancer treatment
ZA945012B (en) Viral vectors and their use in gene therapy
ZA949104B (en) Recombinant viruses and their use in gene therapy
EP0623020A4 (en) Pyropheophorbides and their use in photodynamic therapy.
ZA98497B (en) Medical article with adhered antimicrobial metal ions and related methods
AP9801175A0 (en) Quinoline and quinoline compounds useful in therapy
GB9721909D0 (en) Gene delivery vectors and their uses
ZA949103B (en) Recombinant viruses and their use in gene therapy
IL122094A0 (en) In situ - generated solid radiation source based on tungsten188/rhenium188 and the use thereof
AU1598599A (en) Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
GB9817660D0 (en) Adenoviral vectors encoding erythropoietin and their use in gene therapy
ZA983740B (en) Novel amidine derivatives and their use in therapy
GB9812550D0 (en) Tumour therapy and imaging
EP0863204A4 (en) Human cyclin i and gene encoding the same
EP1023076A4 (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU5871898A (en) Microparticles and their use in cancer treatment
GB9421223D0 (en) Tissue imaging in gene therapy
HUP0104954A3 (en) Prv-1 gene and the use thereof
IL141524A0 (en) Bifunctional antibodies and their use in targeting anti-tumor agents
HUP9900045A3 (en) Improved leukaemic blood-based product and their use in therapy
EP1001966A4 (en) A senescence gene and its use in the treatment of cancer and other diseases
GB9912925D0 (en) Adenoviral vectors encoding interferon and their use in gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)